Looking forward, future research should focus on long-term safety, durability of weight loss, and real-world effectiveness of GLP-1RAs across diverse populations, including those in LMICs
Our recent study addressing this treatment concept showed modest weight-loss effects [30, 31], but further studies with optimized doses are encouraged
Common gastrointestinal side effects include: Nausea and vomiting Diarrhoea or constipation Abdominal pain and bloating Reduced appetite Indigestion These effects typically diminish as the body adjusts to the medication, usually within several weeks
The ECAR profile (Fig
GLP-1 receptor is expressed in human stomach mucosa: Analysis of its cellular association and distribution within gastric glands
[DOI] [PMC free article] [PubMed] [Google Scholar] 46.Koehler JA, Baggio LL, Yusta B, Longuet C, Rowland KJ, Cao X, et al